Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 11/20 | 0.50 |
| ▸ | DPP9 | Q86TI2 | 8/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.50 |
| ▸ | GPR6 | P46095 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2392599 | 1.00 | DPP4 (0.50) | DPP4DPP9DPP7DPP8GPR6 | |
| SCHEMBL2391003 | 1.00 | DPP4 (0.50) | DPP4DPP9DPP7DPP8GPR6 | |
| SCHEMBL2392291 | 0.93 | DPP4 (0.46) | DPP4DPP9DPP7DPP8GPR6 | |
| SCHEMBL2369742 | 0.88 | DPP4 (0.39) | DPP4DPP9DPP7DPP8GPR6 | |
| SCHEMBL2369734 | 0.88 | DPP4 (0.39) | DPP4DPP9DPP7DPP8GPR6 | |
| SCHEMBL2390577 | 0.84 | DPP4 (0.39) | DPP4DPP9DPP7DPP8GPR6 | |
| SCHEMBL2390574 | 0.84 | DPP4 (0.39) | DPP4DPP9DPP7DPP8GPR6 | |
| SCHEMBL24997173 | 0.82 | ALDH1A1 (0.43) | KEAP1HTR2AALDH1A1 | |
| SCHEMBL2396231 | 0.81 | CYP4F2 (0.40) | DPP4DPP9DPP7DPP8HTR2A | |
| SCHEMBL2391512 | 0.81 | CYP4F2 (0.40) | DPP4DPP9DPP7DPP8HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2539345-B1 | 4-[CYCLOALKYLOXY(HETERO)ARYLAMINO]-THIENO[2,3-D]PYRIMIDINES HAVING MNK1/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2015-07-22 | — | — | EP | disclosed |
| US-8754079-B2 | Cycloalkyl containing thienopyrimidines for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-17 | — | — | US | disclosed |
| US-20110217311-A1 | CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110217311-A1 | CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DTYMK, CMPK1, UCK2 | DPP4 3522/4885DPP9 1342/4885DPP7 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.